Skip to main content
Posters

Exploring Symptom Burden, Treatment Bother, Physical Function, and Quality of Life by Frailty Status in Patients with Acute Myeloid Leukemia

By December 15, 2023No Comments
Poster: Exploring Symptom Burden, Treatment Bother, Physical Function, and Quality of Life by Frailty Status in Patients with Acute Myeloid Leukemia

Authors: Nicholas C. Coombs, PhD, MSTAT1 , Emily R. Beamon, PhD, MA, MPH1 , Emelly Rusli, MPH2, Debra Wujcik, PHD, RN2, Aaron Galaznik, MD2, Omer Jamy, MD3

1Piedmont Research Strategies, 2Carevive Systems Inc, 3The University of Alabama at Birmingham

Background

  • Evidence-based guidelines for patients with Acute Myeloid Leukemia (AML) acknowledge the importance of frailty status
    when deciding on treatment.
  • Frailty status may also influence patient outcomes throughout cancer treatment.
  • Electronic Patient Reported Outcomes (ePROs) effectively capture the real-world patient experience as it relates to frailty status and health outcomes.
  • Using ePROs, this study explored collective symptom burden, treatment bother, physical function, and quality of life across fit, intermediate, and frail patients with AML.

Methods

  • All consenting adult patients with an AML diagnosis and current evidence of treatment were enrolled in the Carevive PROmPT® remote symptom monitoring platform between September 1, 2020 and March 10, 2023.
  • Demographic and clinical characteristics were captured at baseline, including age, sex, race, frailty status, comorbidities, and social determinants of health.
  • Classification of a patient’s frailty status (fit, intermediate, frail) involved triangulating data from three separate sources:
    • The Modified Geriatric Assessment (mGA) implemented by Carevive
    • The Cancer and Aging Resilience Evaluation (CARE)
      Geriatric survey
    • Patient Reported Functional Status (PRFS) tool
  • Validated psychometric tools were also assessed weekly to capture each outcome of interest, including symptoms (derived from PRO-CTCAE), treatment bother (a single item FACT-GP5), physical function (PROMIS 4a), and quality of life (EORTC QLQ-C30 #29-30).
  • In this study, these longitudinal measures were analyzed and reported over 12 weeks from enrollment in the RSM platform.
    All results were stratified by frailty status.

Conclusion

  • This study illustrates the feasibility of using remote symptom monitoring for gathering data on frailty status, symptom burden, treatment bother, physical function, and quality of life for patients with AML.
  • Findings suggest there may be functional differences in the overall patient experience at different levels of frailty.
  • This further supports the importance of using frailty status in oncology care, especially to identify actionable risk factors for poor health outcomes during cancer treatment.

Click image to enlarge